

CTI BIOPHARMA CORP  
Form 8-K  
September 16, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report: (Date of earliest event reported): September 16, 2014 (September 16, 2014)**

**CTI BIOPHARMA CORP.**

**(Exact name of registrant as specified in its charter)**

**Washington**  
**(State or other jurisdiction of**  
**incorporation or organization)**

**001-12465**  
**(Commission**  
**File Number)**  
**3101 Western Avenue, Suite 600**

**91-1533912**  
**(I.R.S. Employer**  
**Identification Number)**

Edgar Filing: CTI BIOPHARMA CORP - Form 8-K

**Seattle, Washington 98121**

**(Address of principal executive offices)**

**Registrant's telephone number, including area code: (206) 282-7100**

**Not applicable**

**(Former name or former address, if changed since last report).**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01. Regulation FD Disclosure.**

On September 16, 2014, members of management at CTI BioPharma Corp. (the Company ) will be providing a corporate update to analysts and investors through a series of one-on-one meetings. The slides to be used in these presentations are attached as Exhibit 99.1 hereto.

The slides to be used in these presentations are attached as Exhibit 99.1 hereto and are being furnished and not filed pursuant to Item 7.01 of Form 8-K. Such information shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act ), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act whether made before or after the date hereof and regardless of any general incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits.**

*(d) Exhibits*

**Exhibit**

<b>No.</b>	<b>Description</b>	<b>Location</b>
99.1	CTI BioPharma Corp. Presentation Slides.	Furnished herewith.

**SIGNATURE**

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CTI BIOPHARMA CORP.

Date: September 16, 2014

By: /s/ Louis A. Bianco  
**Louis A. Bianco**  
**Executive Vice President, Finance and**  
**Administration**

**EXHIBIT INDEX**

**Exhibit**

<b>No.</b>	<b>Description</b>	<b>Location</b>
99.1	CTI BioPharma Corp. Presentation Slides.	Furnished herewith.